WO2002030983A3 - Bikunin enthaltende plasmafraktion, verfahren zu ihrer herstellung und ihrer verwendung - Google Patents

Bikunin enthaltende plasmafraktion, verfahren zu ihrer herstellung und ihrer verwendung Download PDF

Info

Publication number
WO2002030983A3
WO2002030983A3 PCT/EP2001/011994 EP0111994W WO0230983A3 WO 2002030983 A3 WO2002030983 A3 WO 2002030983A3 EP 0111994 W EP0111994 W EP 0111994W WO 0230983 A3 WO0230983 A3 WO 0230983A3
Authority
WO
WIPO (PCT)
Prior art keywords
bikunin
plasma fraction
production
same
fraction containing
Prior art date
Application number
PCT/EP2001/011994
Other languages
English (en)
French (fr)
Other versions
WO2002030983A2 (de
Inventor
Djuro Josic
Original Assignee
Octapharma Ag
Djuro Josic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Octapharma Ag, Djuro Josic filed Critical Octapharma Ag
Priority to JP2002534368A priority Critical patent/JP2004511492A/ja
Priority to EP01986698A priority patent/EP1326893A2/de
Priority to AU2002216968A priority patent/AU2002216968A1/en
Publication of WO2002030983A2 publication Critical patent/WO2002030983A2/de
Publication of WO2002030983A3 publication Critical patent/WO2002030983A3/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Verfahren zur Herstellung einer Bikunin-Plasmafraktion mit Antitrypsin Aktivität, wobei eine die Bikunin-Plasmafraktion enthaltende Quelle mittels Molekularausschluss-Chromatographie in Komponenten getrennt wird und eine Fraktion mit Antitrypsin Aktivität gesammelt wird.
PCT/EP2001/011994 2000-10-13 2001-10-11 Bikunin enthaltende plasmafraktion, verfahren zu ihrer herstellung und ihrer verwendung WO2002030983A2 (de)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2002534368A JP2004511492A (ja) 2000-10-13 2001-10-11 ビクニンを含む血漿画分、その調製方法、およびその使用
EP01986698A EP1326893A2 (de) 2000-10-13 2001-10-11 Bikunin enthaltende plasmafraktion, verfahren zu ihrer herstellung und ihrer verwendung
AU2002216968A AU2002216968A1 (en) 2000-10-13 2001-10-11 Plasma fraction containing bikunin, method for the production thereof and use of the same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10050665 2000-10-13
DE10050665.8 2000-10-13

Publications (2)

Publication Number Publication Date
WO2002030983A2 WO2002030983A2 (de) 2002-04-18
WO2002030983A3 true WO2002030983A3 (de) 2002-12-12

Family

ID=7659599

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/011994 WO2002030983A2 (de) 2000-10-13 2001-10-11 Bikunin enthaltende plasmafraktion, verfahren zu ihrer herstellung und ihrer verwendung

Country Status (5)

Country Link
US (1) US20030190732A1 (de)
EP (1) EP1326893A2 (de)
JP (1) JP2004511492A (de)
AU (1) AU2002216968A1 (de)
WO (1) WO2002030983A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007536206A (ja) * 2003-10-16 2007-12-13 バイエル・ヘルスケア・エルエルシー 尿中トリプシンインヒビターを検出するためのモノクローナル抗体
JP5010920B2 (ja) * 2003-11-08 2012-08-29 プロセラ・バイオロジクス 治療に使用するためのヒト血漿由来のインターα阻害タンパク質の調製方法及びその組成物
CN101160133B (zh) * 2004-11-05 2013-01-09 普罗瑟拉生物公司 治疗用途的来自人血浆的内-α抑制剂蛋白质的制备和组合物
CN103142650B (zh) * 2004-11-05 2016-05-11 普罗瑟拉生物公司 治疗用途的来自人血浆的内-α抑制剂蛋白质的制备和组合物
FR2894145B1 (fr) * 2005-12-07 2008-10-17 Lab Francais Du Fractionnement Utilisation de facteur h du complement a titre de medicament
TR201808152T4 (tr) 2008-05-28 2018-07-23 Prothera Biologics Inc Kandan inter-alfa inhibitör proteinlerinin hazırlanması ve bunların bileşimi.
AU2010202125B1 (en) 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
US8772462B2 (en) 2010-05-26 2014-07-08 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide
MX2013000958A (es) 2010-07-23 2013-11-20 Baxter Healthcare Sa Fabricación del inhibidor-inter-alfa (iaip) a partir de plasma.
WO2014039987A2 (en) 2012-09-09 2014-03-13 Prothera Biologics, Inc. Treatment of disease using inter-alpha inhibitor proteins
US20140206844A1 (en) 2013-01-18 2014-07-24 Prothera Biologics Methods for isolating blood products from an inter-alpha inhibitor protein-depleted blood product material
AU2021377336A1 (en) 2020-11-16 2023-07-06 Prothera Biologics, Inc. Methods for purifying inter-alpha inhibitor proteins

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5777081A (en) * 1993-10-18 1998-07-07 Association Pour L'essor De La Transfusion Sanguine Dans La Region Du Nord Process for producing an inter-alpha-trypsin inhibitor concentrate for therapeutic use and concentrate thus obtained
US5846763A (en) * 1991-01-14 1998-12-08 New York University DNA encoding tumor necrosis factor stimulated gene 6 (TSG-6)

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5846763A (en) * 1991-01-14 1998-12-08 New York University DNA encoding tumor necrosis factor stimulated gene 6 (TSG-6)
US5777081A (en) * 1993-10-18 1998-07-07 Association Pour L'essor De La Transfusion Sanguine Dans La Region Du Nord Process for producing an inter-alpha-trypsin inhibitor concentrate for therapeutic use and concentrate thus obtained

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ATMANI ET AL: "Role of inter-alpha-inhibitor and its related proteins in urolithiasis. Purification of an inter-alpha-inhibitor related protein from the bovine kidney.", UROLOGICAL RESEARCH, vol. 27, 1999, pages 57 - 61, XP000994523 *
JOSIC ET AL: "Size-exclusion chromatography of plasma proteins with high molecular masses", JOURNAL OF CHROMATOGRAPHY A, vol. 796, no. 2, 20 February 1998 (1998-02-20), pages 289 - 298, XP004110809, ISSN: 0021-9673 *

Also Published As

Publication number Publication date
US20030190732A1 (en) 2003-10-09
AU2002216968A1 (en) 2002-04-22
WO2002030983A2 (de) 2002-04-18
EP1326893A2 (de) 2003-07-16
JP2004511492A (ja) 2004-04-15

Similar Documents

Publication Publication Date Title
WO2002030983A3 (de) Bikunin enthaltende plasmafraktion, verfahren zu ihrer herstellung und ihrer verwendung
WO2006006161A3 (en) Improved process for the preparation of oxidized phospholipids
IL165988A0 (en) Process for the preparation of fibrinogen
WO2002030870A3 (de) Substituierte c-cyclohexylmethylamin-derivate
PT1362021E (pt) Processo de extracção, de fraccionamento e de purificação de compostos polifenólicos provenientes dos restos de triagem de vegetais frescos usando uma resina de elevado rendimento e de levada eluição
HK1047754A1 (en) Separation of fibrinogen from plasma proteases
MY128409A (en) Process for the isolation and purification of epothilones
AU2895397A (en) Novel substance library and supramolecular complexes prepared therewith
WO2001049654A3 (de) Substituierte aminomethyl-phenyl-cyclohexanderivate
WO2002012533A3 (en) Fermentation and purification of mycolactones
AU2002234051A1 (en) Process for the production of polycarbonate
MXPA03009806A (es) Derivados de piperazino y su uso como inhibidor de fosfodiesterasa de nucleotido ciclico de tipo 4 (pde4).
AU2001272433A1 (en) Method for producing transition metal compounds and their use for the polymerization of olefins
ID24501A (id) Proses produksi metil metakrilat
DE60233064D1 (de) Analgetisches antitumorpeptid aus skorpionen und verfahren zu dessen herstellung
IL154040A0 (en) Method for purifying 2-chloro-5-chloromethyl thiazole
AU7652100A (en) Method for extracting bacterio-rhodopsin
AU2001250429A1 (en) Method for producing 2-alkyl-3-chlorophenols
MY127328A (en) 5-amino-1-pentene-3-ol substituted derivatives
WO2002004010A3 (en) Inhibition of tumor growth by a nematode anticoagulant protein
SE0203551D0 (sv) Prothrombin purification
EP1553073A4 (de) Verfahren zur herstellung von 1,2,4-butantriol
WO2001019989A3 (en) Method of producing and purifying endostatintm protein
WO2001077079A3 (en) Polycyclic aryl and heteroaryl substituted 4-pyridones useful for selective inhibition of the coagulation cascade
WO2002020490A3 (en) Process to produce halo-4-phenoxyquinolines

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 10381440

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2002534368

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2001986698

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001986698

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2001986698

Country of ref document: EP